Stephen Allan Smith

USPTO Granted Patents = 42 (Patent Applications = 8)

CIPO Patents = 6 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 9)

Average Co-Inventor Count = 3.2

ph-index = 9

Forward Citations = 206(Granted Patents)

Location History:

Leeds, GB (1989)
Harlow, GB (2003 - 2010)
Hertfordshire, GB (2014)
Bishop's Stortford, GB (2000 - 2018)
Stevenage, GB (2005 - 2019)
Essex, GB (2014 - 2019)
Bishops Stortford, GB (2023)

Company Filing History:

Smithkline Beecham Corporation

Modern Biosciences Limited

patents

6. 1 out of 92

Glaxosmithkline Intellectual Property (no.2) Limited

patents

7. 1 out of 1

Istesso Therapeutics Limited

patent

8. 1 out of 832,680

Other

patents

Years Active: 1989-2025

Loading Chart...

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240814 - 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use (2025-03-04),

2. 12162836 - N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use (2024-12-10),

3. 11834414 - 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use (2023-12-05),

4. 10233147 - N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use (2019-03-19),

5. 10202386 - Pyrrolo[3,2-D]pyrimidine derivatives as inducers of human interferon (2019-02-12),

6. 10117873 - 6-amino-purin-8-one compounds (2018-11-06),

7. 10029979 - N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use (2018-07-24),

8. 10022442 - Pyrazolopyrimidine compounds (2018-07-17),

9. 10005733 - N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use (2018-06-26),

10. 9907847 - Pyrrolopyrimidines as therapeutic agents for the treatment of diseases (2018-03-06),

11. 9877968 - 6-amino-purin-8-one compounds (2018-01-30),

12. 9796670 - N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use (2017-10-24),

13. 9662336 - Pyrazolopyrimidine compounds (2017-05-30),

14. 9624167 - N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use (2017-04-18),

15. 9555036 - Pyrazolopyrimidine compounds (2017-01-31),

Title: Stephen Allan Smith: Innovator in Therapeutic Compounds

Introduction: Stephen Allan Smith, an accomplished inventor based in Stevenage, GB, has made significant contributions to the field of therapeutics with an impressive portfolio of 38 patents. His innovative work focuses on compounds that address various health conditions, showcasing his deep understanding of medicinal chemistry and its applications.

Latest Patents: Among his latest inventions are the patents for N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides. These compounds, collectively referred to as HMC compounds, are designed to treat a range of disorders, including inflammatory and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Additionally, these compounds focus on combating various types of cancer and conditions associated with excessive immune system activation. Another of his notable inventions includes pyrrolo[3,2-D]pyrimidine derivatives, which serve as inducers of human interferon, showing promise for therapeutic uses in cancer treatment and allergic diseases.

Career Highlights: Stephen Allan Smith has garnered extensive experience in the pharmaceutical industry through his roles in prominent companies such as GlaxoSmithKline LLC and SmithKline Beecham Corporation. His work emphasizes the importance of innovative therapeutic solutions and has positioned him as a notable figure within the pharmaceutical research community.

Collaborations: Throughout his career, Stephen has collaborated with distinguished colleagues, including Diane Mary Coe and Colin Andrew Leach. These partnerships have undoubtedly contributed to the success and development of his innovative compounds, enhancing the potential for new therapeutic applications.

Conclusion: With a remarkable number of patents and a focus on addressing critical health issues, Stephen Allan Smith continues to be a leading inventor in the field of therapeutic compounds. His dedication to innovation and collaboration signifies a promising future for advancements in medical treatment, potentially improving countless lives worldwide.

This text is generated by artificial intelligence and may not be accurate.